Novartis has agreed to acquire the U.S.-based biopharmaceutical company The Medicines Company for $9.7 billion. Under the terms of the deal, Novartis will offer $85 per share in cash. The transaction is expected to close in the first quarter of 2020.
The S&C team advising Novartis is led by corporate partners Frank Aquila
, Matt Hurd
and Melissa Sawyer
, associates Julia Kim, Natalie Lum-Tai and Franklin Liu, partners Ron Creamer (tax), Mehdi Ansari
(intellectual property), Heather Coleman
(executive compensation), Neal McKnight
(financing), Eric Kadel
(CFIUS), Renata Hesse
and Michael Rosenthal
(antitrust) and special counsel Matt Brennan
The Medicines Company focuses on researching treatments for cardiovascular disease, specifically looking at ways to lower so-called bad cholesterol. Its experimental treatment inclisiran uses a new approach to lower bad cholesterol in especially hard-to-treat patients. The treatment will join a line-up of Novartis products that includes the heart-failure treatment Entresto.